Why are the first 8 weeks after stopping so important?

The 8-week window is when appetite regulation shifts back toward baseline, when weight trajectory reveals itself, and when the habits built during treatment either carry the loss forward or don't. It's the window where course-correction is still small; after that, corrections tend to be larger.

When will I notice hunger coming back?

For most people, hunger becomes distinctly noticeable in weeks 1–2 and drifts back toward pre-treatment baseline over weeks 4–8. Tirzepatide (Mounjaro, Zepbound) tends to produce a faster rebound than semaglutide (Ozempic, Wegovy) because it clears the system faster.

How much weight regain is normal in the first 8 weeks?

A 1–3% weight uptick in the first 8 weeks is common and does not negate GLP-1 results. Trial data suggests the steeper part of the regain curve tends to unfold over months 3–12, not the first 8 weeks — but the habit pattern established in the first 8 weeks is what shapes that longer curve.

Do side effects like nausea persist after stopping?

No. GI side effects — nausea, early fullness, constipation — tend to fade within days of the last dose, well before appetite suppression does. This is often the first change people notice after stopping.

What's the single most important thing to focus on in weeks 1–8?

Protein intake. It's the most effective lever for protecting lean mass while appetite rebuilds, and the habit most likely to slip once GI side effects fade and food becomes more appealing again. A target of roughly 0.7–1 g per pound of goal body weight is the standard reference range for GLP-1 discontinuation.

Should I weigh myself daily during this period?

Weekly is usually more useful than daily. Post-cessation, water weight and appetite-driven food volume shift produce day-to-day noise that isn't meaningful — the trend line matters, not any single number. Consistent same-day-of-week weigh-ins are the most decoded signal.

The First 8 Weeks After Your Last GLP-1 Dose

Written by the GLP-1 Coach editorial team. Last updated August 13, 2026.

Most content about GLP-1 medications covers what happens when you start. Much less exists on what happens when you stop — and even less on the specific week-by-week timeline of what your body is doing as the drug clears and appetite regulation rebuilds.

Here is that timeline, grounded in what's actually measurable (pharmacokinetics, STEP-1 extension weight-trajectory data) and honest where the day-to-day subjective data hasn't been formally studied.

Week 1: The drug is still doing most of its work

You are, pharmacologically, still on the medication for most of this week. Semaglutide's half-life of about 7 days means roughly half the drug from your last dose is still in your system at day 7. Tirzepatide's 5-day half-life means about half is still there at day 5.

What actually changes:

GI side effects fade quickly. Nausea, early fullness, constipation, and slowed gastric emptying start easing within days of the last dose. For many people this is the first noticeable change — food feels more normal to eat than it has in months.
Appetite is still meaningfully suppressed. You may notice a subtle uptick in hunger toward the end of the week, particularly in the mid-afternoon or evening windows that tended to be quietest on treatment, but it's rarely dramatic.
Weight is stable or still decreasing. Because appetite suppression is largely intact, most people don't see any regain movement in week 1.

What to focus on: treat this like a normal week on the medication. Protein target, meal structure, water — all the same. The point isn't to prepare for a crisis; it's to keep the routine that was working, because that routine is the actual protection for weeks 3 onward.

Week 2: Appetite starts to come back distinctly

By the end of week 2, semaglutide levels are down to about 25% of the last dose peak; tirzepatide is closer to 13%. This is usually the first week where hunger changes are hard to miss.

Hunger becomes more physical and more frequent. Meals feel less "sufficient" than they did on medication. Between-meal windows feel longer.
Ghrelin rebounds. The hunger hormone that GLP-1s partly work around begins moving back toward, and sometimes briefly overshoots, pre-treatment baseline. This is normal physiology, not a signal of anything going wrong.
Food starts sounding appealing again. For people who described a "quieting" of food thoughts on medication, this is often the week that shifts.

What to focus on: hit your protein target without exception. The single most reliable habit for protecting weight loss and lean mass through the transition is a consistent daily protein floor — commonly 0.7–1 g per pound of goal body weight. This is the week that number stops being easy and starts being work.

Week 3: The rebound becomes real for most people

Semaglutide is down to about 12.5% of peak; tirzepatide is functionally 90% cleared. This is often the week when the difference between "on the drug" and "off the drug" is unmistakable.

Appetite is back to something close to pre-treatment for many people. Not always at full baseline yet, but distinctly different from week 1.
Portion size feels harder to control by feel alone. The internal "I'm full" signal that ran on autopilot during treatment is less reliable. Structured meals (planned portion, planned protein) tend to work better than intuitive eating in this window.
Cravings can spike — including for foods you didn't miss on medication. This is expected as reward pathways recalibrate.

What to focus on: structure over willpower. Same meals, same times, same protein anchor. Decision fatigue is loudest when hunger is loudest, and pre-decided meals are the cheapest way to route around it.

Week 4: The one-month mark and the first meaningful weight check

Semaglutide is down to about 6%; tirzepatide is functionally cleared. Appetite is closer to pre-treatment baseline for most people by the end of this week.

Weight trajectory becomes readable for the first time. Before week 4, weight noise from GI changes and food volume shifts makes trend spotting unreliable. From week 4 on, a genuine trend line starts to appear.
A 1–3% uptick is common and not concerning. Weight typically settles slightly higher than the on-medication low as glycogen and water rehydrate at higher food volumes. This is water and stored carbohydrate, not fat regain.
Food noise returns unpredictably. Some people are still relatively quiet mentally around food at week 4; others describe it as fully back by then. Neither is unusual.

What to focus on: compare this week's weight to two weeks ago, not to your on-medication low. What matters is the direction, not the delta from your best number.

Week 5: Habits are the only protection now

Semaglutide is functionally cleared for most people at this point. Whatever the drug was doing for appetite regulation is no longer available to lean on.

The medication is no longer an active variable. Everything from this point forward is behavioral and physiologic — the drug's contribution to any weight outcome has ended.
Sleep and stress start mattering more visibly. Both affect appetite regulation significantly, and both were easier to override with active appetite suppression. Now they show up in day-to-day hunger patterns more directly.
Resistance activity becomes a bigger lever. Whatever muscle-preserving exercise you did during treatment matters more now, because you're now depending on lean mass to defend the maintained weight rather than appetite suppression.

What to focus on: add or maintain resistance training if it isn't already there. Even twice per week meaningfully reduces muscle loss and supports resting metabolic rate during the appetite-return phase.

Weeks 6–7: The trajectory reveals itself

By weeks 6 and 7, the pattern of the next several months is largely visible. This is not because the physiology has "settled" (it's still adjusting), but because the habit stability by this point tends to be predictive of the following six to twelve months.

Weight trend in this window is a strong predictor of the 3–6-month outcome. People whose weight has drifted 2–4% up from their on-medication low by week 6 tend to see a slower, more manageable regain curve than people whose weight has drifted 5%+ up by the same point.
Small course-corrections are much easier than larger ones later. A 2% uptick is a routine adjustment; a 6% uptick is a project. Watching the trend closely now is exponentially cheaper than dealing with it later.
Some people never regain meaningfully. In the STEP-1 extension study, participants collectively regained about two-thirds of the weight they lost over the year following cessation — but that's a group average, and the distribution is wide. Habit consistency is one of the largest sources of that variance.

What to focus on: don't cut calories reflexively if the scale ticks up. Reflexive calorie cuts in this window compound as muscle loss, which slows metabolism, which makes the next uptick more likely. Add protein and structure before subtracting food.

Week 8: The two-month mark

You are now, both pharmacologically and behaviorally, "off" the medication in every meaningful sense. Whatever the picture looks like at week 8 — protein consistency, weight trend, hunger management, resistance activity — is a strong signal of what the next several months will look like at your current trajectory.

The regain curve from here is generally slower than what unfolded weeks 1–4. In trial data, the steepest part of the post-cessation weight trajectory tends to unfold over months 3–12 — but at a much lower rate per week than the initial adjustment.
Habit durability, not appetite suppression, is what carries the loss forward. This is the point where the framing of GLP-1 treatment as "temporary appetite support to build durable habits" either paid off or didn't.
A weekly rhythm of protein + weight + resistance activity is the maintenance stack most likely to hold. Complexity beyond that tends to erode over months; simplicity tends to persist.

What to focus on: treat week 8 as the actual start of your maintenance phase, not the ending of your medication phase. Everything from here is durability, not adjustment.

What if I stopped tirzepatide instead of semaglutide?

The timeline compresses. Because tirzepatide clears in roughly 3–4 weeks vs semaglutide's ~5, the appetite rebound generally arrives 1–2 weeks earlier. Week 2 on this timeline looks more like week 3 for tirzepatide users; the appetite-back-to-baseline point often lands closer to weeks 3–4 than weeks 5–6.

The SURMOUNT-4 trial provides the clearest reference: over the year after tirzepatide cessation, participants regained about 14 percentage points of body weight on average (vs about 5% additional loss for those who continued the drug). The trajectory started sooner and moved faster than the equivalent semaglutide data.

Everything else on this timeline — habit focus, protein target, resistance activity, weight-trend awareness — is the same.

The bottom line

Bottom line: Weeks 1–2 fade GI side effects and gently return hunger. Weeks 3–4 bring appetite back distinctly. Weeks 5–8 are where habits carry the weight loss forward or don't. The 1–3% uptick common in weeks 4–6 isn't regain — it's rehydration. The trajectory visible at week 8 is a strong signal for the next 6–12 months.

Related tool: our free post-therapy timeline calculator applies this exact framework to your specific last-dose date.

Final Thoughts

The 8-week window is not an afterthought to the "real" part of GLP-1 treatment. In trial data and in real-world experience, it's the window that most directly determines whether the weight loss holds or drifts. Almost everything published about GLP-1s focuses on the phase where the medication is doing the work; this is the phase where you're doing it.

Most people don't realize until they're in this window that the medication was masking, not replacing, the habit work. That's not a criticism of the drug — it's the entire point of it. But the transition off it is a distinct phase with its own physiology and its own required attention, and treating it that way is one of the highest-leverage things you can do to protect months or years of progress.

If you're on medication now, weeks 6–8 of your on-therapy schedule are the ideal window to start rehearsing the habits that will need to carry you through weeks 6–8 of your off-therapy schedule. The habits transfer; the appetite suppression doesn't.

This article is educational and not a substitute for medical advice. Decisions about stopping, tapering, or resuming any GLP-1 medication should be made with your prescriber.

Sources: Wilding et al., STEP 1 extension, Diabetes, Obesity and Metabolism 2022; Aronne et al., SURMOUNT-4, JAMA 2023; Wegovy prescribing information, FDA; Mounjaro prescribing information, Eli Lilly; WHO GLP-1 Obesity Guideline, December 2025.